Previous epidemiological studies have indicated inconsistent results regarding the correlation between antidepressant use and ovarian cancer risk.
Hyperthermic intraperitoneal chemotherapy with surgery increases survival for epithelial ovarian cancer patientsJanuary 22, 2018
Ovarian cancer has high rates of mortality as it is often diagnosed in late stages with spread to the peritoneal surface.
Females with BRCA1 mutations in their germline have a high risk of HGSOC.
Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.
Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.
Eligible patients had platinum-sensitive malignancies, had at least 2 previous platinum-based therapies, and had reached complete or partial response to the most recent platinum-based regimen.
First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).
Researchers examined the differences in outcomes in patients with ovarian cancer who received platinum-based chemotherapy and non-platinum based chemotherapy after relapse.
Patients in the olaparib arm experienced a 70% reduction in the risk of disease progression or death vs placebo.
Maintenance treatment with olaparib tablets may prolong PFS without negatively affecting quality of life among patients with relapsed ovarian cancer.
Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy.
Durvalumab plus olaparib or intermittent cediranib is clinically active and tolerable in treating female cancers.
This anti-CD27 antibody demonstrated clinical activity among and was well-tolerated by patients with solid tumors including melanoma, prostate cancer, and renal cell carcinoma.
Safety, tolerability, and efficacy of palbociclib in combination with cisplatin or carboplatin among patients with advanced/metastatic solid tumors.
Adding bevacizumab to platinum-based chemotherapy may improve survival among women with recurrent ovarian cancer.
Study findings show that "important disparities in use of end-of-life care persist among racial and ethnic minorities."
Approval was based on findings from the phase 3 NOVA trial, the results of which were published in The New England Journal of Medicine.
Access a detailed treatment regimen chart for ovarian cancer, with a focus on primary chemotherapy/primary adjuvant therapy with IV and IP options.
Combined liquid-based Pap and CT-DNA may be a new method for tumor-derived driver mutation screening in primary ovarian carcinoma.
Patients with newly diagnosed ovarian cancer rank nausea as the most concerning side effect associated with chemotherapy.
Study results suggest that carefully selected elderly patients with recurrent or refractory gynecologic malignancy should be enrolled in phase 1 trials.
Hypermethylation of HRR-associated genes was not associated with improved survival in ovarian cancer.
Adjuvant platinum-based chemotherapy did not improve survival in women with low-grade serous ovarian cancer.
BRCA1 and RAD51C methylation in ovarian carcinomas are associated with sensitivity to PARP inhibitors, such as rucaparib.
The Hospital Readmission Reduction Program may unfairly penalize hospitals if 30-day readmission rates are the only metric for care quality.
Gynecologic oncologists are at a particularly high risk for burnout compared with other specialties, suggesting a need for burnout prevention and wellness programs.
Hormonal maintenance therapy after primary treatment significantly prolonged progression-free survival compared with observation,
Acquired reversion mutations in BRCA1/2 are detectable in circulating cell-free DNA (cfDNA) in women with high-grade serous ovarian cancer (HGSC).
Tesaro has opened an EAP to make niraparib available to eligible women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Treatment with diagnostic laparoscopy rather than primary surgery may lower the rate of futile laparotomies among women with suspected advanced ovarian cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma